Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA- Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Volunteer?

Melhem M Solh, MD, Xu Zhang, PhD, Scott R Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2017) 130 (Supplement 1): 4604.

https://doi.org/10.1182/blood.V130.Suppl_1.4604.4604

Published: 2017

Journal Articles

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Asad Bashey, MD PhD, Xu Zhang, PhD, Stacey Brown, CCRP, Katelin C Jackson, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem M Solh, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 4608.

https://doi.org/10.1182/blood.V130.Suppl_1.4608.4608

Published: 2017

Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2662.

https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662

Published: 2017

Journal Articles

Myeloablative Hematopoietic Cell Transplantation (HCT) for Low and Intermediate Disease Risk Index Myeloid Malignancies Results in Better Outcomes Compared to Reduced Intensity HCT

Melhem M Solh, MD, Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 2050.

https://doi.org/10.1182/blood.V130.Suppl_1.2050.2050

Published: 2017

Journal Articles

Identifying Risk Factors for Acute and Chronic Graft-Versus-Host Disease in T-Replete HLA-Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Jimena Baron, Michelle Ridgeway, Xu Zhang, PhD, Asad Bashey, MD PhD, Scott R Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Melhem M Solh, MD

Blood (2017) 130 (Supplement 1): 1977.

https://doi.org/10.1182/blood.V130.Suppl_1.1977.1977

Published: 2017

Journal Articles

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Carmelo Carlo-Stella, MD, Erin Reid, MD, Jay Feingold, MD PhD, Kirit M Ardeshna, MD, John Radford, MD, Melhem M Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, Shui He, PhD, Joseph Boni, PhD, Owen Anthony O'Connor, MD

Blood (2017) 130 (Supplement 1): 187.

https://doi.org/10.1182/blood.V130.Suppl_1.187.187

Published: 2017

Journal Articles

Selecting the Best Donor for T Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables

Scott R Solomon, MD, Michael A Aubrey, CHS, Xu Zhang, PhD, Allison Piluso, Brian M Freed, PhD DABHI, Stacey Brown, CCRP, Katelin C Jackson, Melhem M Solh, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2017) 130 (Supplement 1): 670.

https://doi.org/10.1182/blood.V130.Suppl_1.670.670

Published: 2017

Journal Articles

Method of Mobilization: Implication on Cell Subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation (AHCT)

Melhem M. Solh, MD, Rathmann Kristin, MS, Sauvi chang-Fong, Jeremiah Oyer, Wesam B. Ahmed, MD PhD, Alicja J Copik, PhD, Yasser Khaled, MD

Blood (2014) 124 (21): 1132.

https://doi.org/10.1182/blood.V124.21.1132.1132

Published: 2014

Journal Articles

Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation

Sauvi chang-Fong, Kristin Rathmann, Julie Pepe, Yasser Khaled, MD, Alicja J Copik, PhD, Jeremiah Oyer, Melhem M. Solh, MD

Blood (2014) 124 (21): 3823.

https://doi.org/10.1182/blood.V124.21.3823.3823

Published: 2014

Journal Articles

In Vitro Preactivation of PBMCs with PM-mb21-41BBL Particles Stimulates in Vivo Expansion of NK Cells Under Low IL-2 in NSG Mice

Jeremiah L Oyer, Veethika Pandey, Robert Y Igarashi, PhD, Dominic A Colosimo, Melhem M. Solh, MD, Deborah A Altomare, PhD, Alicja J Copik, PhD

Blood (2014) 124 (21): 3842.

https://doi.org/10.1182/blood.V124.21.3842.3842

Published: 2014

Journal Articles

Effect Of Plerixafor Mobilization On Immune Reconstitution Post High Dose Chemotherapy and Autologous Stem Cell Transplantation

Melhem M. Solh, MD, Tori Smith, Yasser Khaled, MD, Alicja Copik, PhD

Blood (2013) 122 (21): 2031.

https://doi.org/10.1182/blood.V122.21.2031.2031

Published: 2013

Journal Articles

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid Leukemia/ Myelodysplastic Syndrome Conditioned With Intravenous Busulfan and Fludarabine

Yasser Khaled, MD, Megan Smith, Tori Smith, Jason Balls, Abraham Matar, Deborah Lamontagne, Roy M. Ambinder, MD, Ahmed Zakari, MD, Melhem M. Solh, MD

Blood (2013) 122 (21): 5453.

https://doi.org/10.1182/blood.V122.21.5453.5453

Published: 2013

Journal Articles

Generation Of Clinical Grade, Highly Cytotoxic NK Cells Using Feeder Cell Free, Particle-Based Technology

Jerremiah Oyer, Igarashi Y Robert, Ph.D., Colosimo Dominic, Melhem M. Solh, MD, Yasser Khaled, MD, Alicja J Copik, PhD

Blood (2013) 122 (21): 4503.

https://doi.org/10.1182/blood.V122.21.4503.4503

Published: 2013

Journal Articles

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Melhem M. Solh, MD, Tori Smith, Jason Balls, Megan Smith, Yasser Khaled, MD

Blood (2013) 122 (21): 5497.

https://doi.org/10.1182/blood.V122.21.5497.5497

Published: 2013

Journal Articles

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) For Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Following Intravenous Busulfan/Fludarabine Based Conditioning: Outcomes and Monocyte Chemo-Attractant Protein -1( MCP-1) As a Predictive Marker Of Relapse

Abraham Matar, BS, Melhem M. Solh, MD, Alicja J Copik, PhD, Sally Litherland, PhD, Alvin oliverasAlmodovar, Kristin Rathmann, Yasser Khaled, MD

Blood (2013) 122 (21): 3325.

https://doi.org/10.1182/blood.V122.21.3325.3325

Published: 2013

Journal Articles

Leukocytosis Post Engraftment Is Associated with Increased Mortality Among Adult Allogeneic Hematopoietic Cell Transplant (HCT) Reciepients

Melhem M. Solh, MD, Yasser Khaled, MD

Blood (2012) 120 (21): 4536.

https://doi.org/10.1182/blood.V120.21.4536.4536

Published: 2012

Journal Articles

Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation

Yasser Khaled, MD, Melhem M. Solh, MD, David Ward, Chung-Che Chang, MD, PhD

Blood (2012) 120 (21): 4538.

https://doi.org/10.1182/blood.V120.21.4538.4538

Published: 2012

Journal Articles

Physician's Experience and Continuity of Care May Result in Superior Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies with Standard Conditioning Regimens and GVHD Prophylaxis

Yasser Khaled, MD, Melhem M. Solh, MD

Blood (2012) 120 (21): 4715.

https://doi.org/10.1182/blood.V120.21.4715.4715

Published: 2012

Journal Articles

The Impact of Continuity of Care On Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation; Improved Overall Survival in the Absence of Severe Graft Vs. Host Disease

Yasser Khaled, MD, Melhem M. Solh, MD, Robert B. Reynolds, MD, Carlos Alemany, MD, Raul Castillo, MD, Sarah George, MD, Linda Lukman, MD, Ahmed Zakari, MD, Lee Zehngebot, MD

Blood (2012) 120 (21): 4521.

https://doi.org/10.1182/blood.V120.21.4521.4521

Published: 2012

NARROW

Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA- Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Volunteer?

Comparison of Outcomes Following Allogeneic HCT for Adverse Cytogenetic/Molecular Risk AML Using T-Replete Haploidentical Donors to Optimally Matched Related and Unrelated Donors

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Myeloablative Hematopoietic Cell Transplantation (HCT) for Low and Intermediate Disease Risk Index Myeloid Malignancies Results in Better Outcomes Compared to Reduced Intensity HCT

Identifying Risk Factors for Acute and Chronic Graft-Versus-Host Disease in T-Replete HLA-Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Selecting the Best Donor for T Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables

Method of Mobilization: Implication on Cell Subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation (AHCT)

Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation

In Vitro Preactivation of PBMCs with PM-mb21-41BBL Particles Stimulates in Vivo Expansion of NK Cells Under Low IL-2 in NSG Mice

Effect Of Plerixafor Mobilization On Immune Reconstitution Post High Dose Chemotherapy and Autologous Stem Cell Transplantation

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid Leukemia/ Myelodysplastic Syndrome Conditioned With Intravenous Busulfan and Fludarabine

Generation Of Clinical Grade, Highly Cytotoxic NK Cells Using Feeder Cell Free, Particle-Based Technology

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) For Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Following Intravenous Busulfan/Fludarabine Based Conditioning: Outcomes and Monocyte Chemo-Attractant Protein -1( MCP-1) As a Predictive Marker Of Relapse

Leukocytosis Post Engraftment Is Associated with Increased Mortality Among Adult Allogeneic Hematopoietic Cell Transplant (HCT) Reciepients

Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation

Physician's Experience and Continuity of Care May Result in Superior Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies with Standard Conditioning Regimens and GVHD Prophylaxis

The Impact of Continuity of Care On Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation; Improved Overall Survival in the Absence of Severe Graft Vs. Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only